Human CAPN2/CANP2/CANPL2 ORF/cDNA clone-Lentivirus plasmid (NM_001748)

Cat. No.: pGMLP001330
Size: 10 µg
Concentration: generally 0.5ug/ul, usually not less than 0.3ug/ul
Leading Time: 3-7 working days

Pre-made Human CAPN2/CANP2/CANPL2 Lentiviral expression plasmid for CAPN2 lentivirus packaging, CAPN2 lentivirus production, overexpression stable cell line development, cell transient transfection and gene delivery targeting T/B/NK cells, macrophages, cardiomyocytes, hepatocytes, and neurons.

Our GM-Lentiviral vector is seamlessly integrated with the GM lentivirus packaging system. Discover more about the GM lentivirus packaging system.

pdf Datasheet
pdf MSDS
pdf Terms of Use
Target products collection

Go to CAPN2/CANP2 products collection>>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

Purchase
Total Price: $1015.02
Shipping fee: Limited-time free
For payment issues, contact us.


Product Description

Catalog ID pGMLP001330
Gene Name CAPN2
Accession Number NM_001748
Gene ID 824
Species Human
Product Type Lentivirus plasmid (overexpression)
Insert Length 2103 bp
Gene Alias CANP2,CANPL2,CANPml,mCANP
Fluorescent Reporter ZsGreen
Mammalian Cell Selection Puromyocin
Fusion Tag 3xflag (C-Terminal)
Promoter CMV
Resistance Amplicin
ORF Nucleotide Sequence ATGGCGGGCATCGCGGCCAAGCTGGCGAAGGACCGGGAGGCGGCCGAGGGGCTGGGCTCCCACGACAGGGCCATCAAGTACCTCAACCAGGACTACGAGGCGCTGCGGAACGAGTGCCTGGAGGCCGGGACGCTCTTCCAGGACCCGTCCTTCCCGGCCATCCCCTCGGCCCTGGGCTTCAAGGAGTTGGGGCCCTACTCCAGCAAAACCCGGGGCATCGAGTGGAAGCGCCCCACGGAGATCTGCGCTGACCCCCAGTTTATCATTGGAGGAGCCACCCGCACAGACATCTGCCAAGGAGCCCTGGGTGACTGCTGGCTGCTGGCAGCCATTGCCTCCCTCACCTTGAATGAAGAAATCCTGGCTCGAGTCGTCCCCCTAAACCAGAGCTTCCAGGAAAACTATGCAGGGATCTTTCACTTCCAGTTCTGGCAATACGGCGAGTGGGTGGAGGTGGTGGTGGATGACAGGCTGCCCACCAAGGACGGGGAGCTGCTCTTTGTGCATTCAGCCGAAGGGAGCGAGTTCTGGAGCGCCCTGCTGGAGAAGGCATACGCCAAGATCAACGGATGCTATGAAGCGCTATCAGGGGGTGCCACCACTGAGGGCTTCGAAGACTTCACCGGAGGCATTGCTGAGTGGTATGAGTTGAAGAAGCCCCCTCCCAACCTGTTCAAGATCATCCAGAAAGCTCTGCAAAAAGGCTCTCTCCTTGGCTGCTCCATCGACATCACCAGCGCCGCGGACTCGGAGGCCATCACGTTTCAGAAGCTGGTGAAGGGGCACGCGTACTCGGTCACCGGAGCCGAGGAGGTTGAAAGTAACGGAAGCCTACAGAAACTGATCCGCATCCGAAATCCCTGGGGAGAAGTGGAGTGGACAGGGCGGTGGAATGACAACTGCCCAAGCTGGAACACTATAGACCCAGAGGAGAGGGAAAGGCTGACCAGACGGCATGAAGATGGAGAATTCTGGATGTCTTTCAGTGACTTCCTGAGGCACTATTCCCGCCTGGAGATCTGTAACCTGACCCCAGACACTCTCACCAGCGATACCTACAAGAAGTGGAAACTCACCAAAATGGATGGGAACTGGAGGCGGGGCTCCACCGCGGGAGGTTGCAGGAACTACCCGAACACATTCTGGATGAACCCTCAGTACCTGATCAAGCTGGAGGAGGAGGATGAGGACGAGGAGGATGGGGAGAGCGGCTGCACCTTCCTGGTGGGGCTCATTCAGAAGCACCGACGGCGGCAGAGGAAGATGGGCGAGGACATGCACACCATCGGCTTTGGCATCTATGAGGTTCCAGAGGAGTTAAGTGGGCAGACCAACATCCACCTCAGCAAAAACTTCTTCCTGACGAATCGCGCCAGGGAGCGCTCAGACACCTTCATCAACCTCCGGGAGGTGCTCAACCGCTTCAAGCTGCCGCCAGGAGAGTACATTCTCGTGCCTTCCACCTTCGAACCCAACAAGGATGGGGATTTCTGCATCCGGGTCTTTTCTGAAAAGAAAGCTGACTACCAAGCTGTCGATGATGAAATCGAGGCCAATCTTGAAGAGTTCGACATCAGCGAGGATGACATTGATGATGGATTCAGGAGACTGTTTGCCCAGTTGGCAGGAGAGGATGCGGAGATCTCTGCCTTTGAGCTGCAGACCATCCTGAGAAGGGTTCTAGCAAAGCGCCAAGATATCAAGTCAGATGGCTTCAGCATCGAGACATGCAAAATTATGGTTGACATGCTAGATTCGGACGGGAGTGGCAAGCTGGGGCTGAAGGAGTTCTACATTCTCTGGACGAAGATTCAAAAATACCAAAAAATTTACCGAGAAATCGACGTTGACAGGTCTGGTACCATGAATTCCTATGAAATGCGGAAGGCATTAGAAGAAGCAGGTTTCAAGATGCCCTGTCAACTCCACCAAGTCATCGTTGCTCGGTTTGCAGATGACCAGCTCATCATCGATTTTGATAATTTTGTTCGGTGTTTGGTTCGGCTGGAAACGCTATTCAAGATATTTAAGCAGCTGGATCCCGAGAATACTGGAACAATAGAGCTCGACCTTATCTCTTGGCTCTGTTTCTCAGTACTTTGA
ORF Protein Sequence MAGIAAKLAKDREAAEGLGSHDRAIKYLNQDYEALRNECLEAGTLFQDPSFPAIPSALGFKELGPYSSKTRGIEWKRPTEICADPQFIIGGATRTDICQGALGDCWLLAAIASLTLNEEILARVVPLNQSFQENYAGIFHFQFWQYGEWVEVVVDDRLPTKDGELLFVHSAEGSEFWSALLEKAYAKINGCYEALSGGATTEGFEDFTGGIAEWYELKKPPPNLFKIIQKALQKGSLLGCSIDITSAADSEAITFQKLVKGHAYSVTGAEEVESNGSLQKLIRIRNPWGEVEWTGRWNDNCPSWNTIDPEERERLTRRHEDGEFWMSFSDFLRHYSRLEICNLTPDTLTSDTYKKWKLTKMDGNWRRGSTAGGCRNYPNTFWMNPQYLIKLEEEDEDEEDGESGCTFLVGLIQKHRRRQRKMGEDMHTIGFGIYEVPEELSGQTNIHLSKNFFLTNRARERSDTFINLREVLNRFKLPPGEYILVPSTFEPNKDGDFCIRVFSEKKADYQAVDDEIEANLEEFDISEDDIDDGFRRLFAQLAGEDAEISAFELQTILRRVLAKRQDIKSDGFSIETCKIMVDMLDSDGSGKLGLKEFYILWTKIQKYQKIYREIDVDRSGTMNSYEMRKALEEAGFKMPCQLHQVIVARFADDQLIIDFDNFVRCLVRLETLFKIFKQLDPENTGTIELDLISWLCFSVL

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    Category Cat No. Products Name
    Target Antibody GM-Tg-g-T04902-Ab Anti-CAPN2 monoclonal antibody
    Target Antigen GM-Tg-g-T04902-Ag CAPN2 protein
    ORF Viral Vector pGMLP001330 Human CAPN2 Lentivirus plasmid
    ORF Viral Vector vGMLP001330 Human CAPN2 Lentivirus particle


    Target information

    Target ID GM-T04902
    Target Name CAPN2
    Gene ID 824, 12334, 703047, 29154, 101083231, 480118, 281662, 100055184
    Gene Symbol and Synonyms CALP80,CANP2,CANPL2,CANPml,Capa-2,Capa2,CAPN2,m-calpain,m-calpin,mCANP
    Uniprot Accession P17655
    Uniprot Entry Name CAN2_HUMAN
    Protein Sub-location Introcelluar Protein
    Category Therapeutics Target
    Disease Not Available
    Gene Ensembl ENSG00000162909
    Target Classification Not Available

    The calpains, calcium-activated neutral proteases, are nonlysosomal, intracellular cysteine proteases. The mammalian calpains include ubiquitous, stomach-specific, and muscle-specific proteins. The ubiquitous enzymes consist of heterodimers with distinct large, catalytic subunits associated with a common small, regulatory subunit. This gene encodes the large subunit of the ubiquitous enzyme, calpain 2. Multiple heterogeneous transcriptional start sites in the 5' UTR have been reported. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Mar 2009]



    About GMVC

    GDU

    GMVC (GM Vector Core) is GeneMedi’s unique platform for QbD Viral vectors Processes development and manufacturing. In GMVC, our core expertise lies in the tailored production of viral vectors, including adeno-associated virus (AAV), lentivirus, and adenovirus. Our state-of-the-art facilities are equipped for scalable manufacturing, ensuring high-quality viral vector production to meet both research and therapeutic needs. Our expert team specializes in process development, leveraging innovative technology and extensive industry knowledge to provide clients with tailored solutions that exceed expectations. GMVC will be the ideal partner for scientists and healthcare professionals seeking reliable and efficient viral vector production services.